Pharmacologic aspects of new antiretroviral drugs.

Current HIV/AIDS Reports
Mary C LongEdward P Acosta

Abstract

The biggest challenge facing highly antiretroviral-experienced patients and their caregivers is the diminishing number of therapeutic options available that sustain activity despite increasing numbers of drug-resistance mutations. New options in antiretroviral treatment have been introduced: two new members of traditional antiretroviral classes (darunavir and etravirine) and two drugs with novel mechanisms of action (raltegravir and maraviroc). Each was approved for use in treatment-experienced patients. A fifth drug-containing efavirenz, tenofovir, and emtricitabine (Atripla; Bristol-Myers Squibb, New York, NY, and Gilead Sciences, Foster City, CA)-is a novel coformulation of existing drugs from two different classes, simplifying administration with the intent of increasing adherence. Because successful management of HIV infection requires the simultaneous use of three or more drugs, understanding the pharmacologic aspects of coadministration is critical. This review summarizes the pharmacokinetic properties affecting the administration of these recently approved drugs in light of highly active antiretroviral treatment guidelines.

References

Jul 6, 2000·Annals of Internal Medicine·D L PatersonN Singh
Dec 12, 2001·Clinical Pharmacokinetics·P F SmithG D Morse
Sep 23, 2003·Biophysical Chemistry·Arne SchönErnesto Freire
Oct 31, 2003·AIDS Research and Human Retroviruses·Marta BoffitoVeronica Miller
Feb 27, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter L AndersonKenneth A Lichtenstein
Apr 15, 2004·Clinical Pharmacokinetics·Jennifer R KingEdward P Acosta
Aug 21, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Peter J Piliero
Sep 8, 2004·Current Opinion in Pharmacology·Michael J Otto
Nov 13, 2004·The Journal of Antimicrobial Chemotherapy·J FordD J Back
Jul 2, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·David J BackJohn G Gerber
Jan 20, 2006·The New England Journal of Medicine·Joel E GallantUNKNOWN Study 934 Group
Feb 9, 2006·The Journal of Antimicrobial Chemotherapy·Verónica BrizVincent Soriano
Feb 27, 2007·Journal of Theoretical Biology·O Krakovska, L M Wahl
Jun 27, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Kelem KassahunLarissa A Wenning
Aug 21, 2007·Gender Medicine·Ighovwerha OfotokunJane E Hitti
Aug 23, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Zelalem Temesgen, Judith Feinberg
Aug 24, 2007·Clinical Pharmacology and Therapeutics·M IwamotoJ A Wagner
Aug 24, 2007·Clinical Pharmacokinetics·Michael Rittweger, Keikawus Arastéh
Sep 25, 2007·The Journal of Antimicrobial Chemotherapy·Mike Youle
Oct 9, 2007·Clinical Therapeutics·Christopher McCoy
Oct 12, 2007·Drugs·Natalie J Carter, Gillian M Keating
Nov 29, 2007·Therapeutic Drug Monitoring·Vanitha J SekarRichard M W Hoetelmans
Dec 18, 2007·Drugs·Jorge L Martinez-Cajas, Mark A Wainberg
Feb 26, 2008·Journal of Medical Virology·Carlo-Federico PernoMauro Schechter
Mar 1, 2008·Virus Research·Dirk Jochmans
Mar 11, 2008·AIDS Research and Human Retroviruses·Emmanouil MagiorkinisAngelos Hatzakis

❮ Previous
Next ❯

Citations

Jan 31, 2012·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Vicki E HuttonFrancesca E Collins
Nov 26, 2011·BMC Research Notes·Hadija H Semvua, Gibson S Kibiki
Jan 7, 2011·Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria·J I Serrano López de Las Hazas
Oct 27, 2011·The Annals of Pharmacotherapy·Kyle WilbyLarry D Lynd
Dec 6, 2017·Pharmacogenomics·Jessica CusatoAntonio D'Avolio
Oct 5, 2010·Environmental Toxicology and Chemistry·Raúl A Loayza-MuroWim Admiraal
Nov 19, 2009·Clinical Medicine. Therapeutics·Olga LatinovicAlonso Heredia

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.